As part of the urgent global race to tackle the coronavirus outbreak, Novavax (NVAX) is due to commence Phase 1 testing for its …
If you think the broader market’s extreme pendulum swings are the definition of volatility, you should have a conversation with long–term investors of vaccine specialist Novavax (NVAX). To quickly recap the last 24 …
Novavax, Inc. (NASDAQ:NVAX) provided a corporate update and announced its financial results for the fourth quarter and twelve months ended December 31, 2017.
Brace yourself. Novavax, Inc.
Novavax, Inc. (NASDAQ:NVAX) announced the enrollment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including …
Novavax, Inc. (NASDAQ:NVAX) shares were rising 5% in after-hours trading yesterday after the company reported second-quarter financials and provided investors with an update …
Novavax, Inc. (NASDAQ:NVAX) investors are scratching their heads and trying to figure out whether this morning’s drop has created an attractive entry point.
Novavax, Inc. (NASDAQ:NVAX) announced positive topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, …
Novavax, Inc. (NASDAQ:NVAX) announced its financial results for the first quarter ended March 31, 2017.
Novavax, Inc. (NASDAQ:NVAX) shares fell almost 10% in after-market hours on the heels of the firm’s release of fourth-quarter financials and clinical updates.
